AimTo evaluate the effect of intravitreal bevacizumab (Avastin^®) injections on visual acuity and foveal retinal thickness in patients with central and branch retinal vein occlusion (CRVO et BRVO).Material and MethodsRetrospective consecutiveinterventional case series of 60 patients diagnosed with macular edema from CRVO et BRVO who received repeated intravitreal injections (1.25 mg) of bevacizumab. Main outcome measures were visual acuity and optical coherence tomography measurements in a 6-month follow-up period.ResultsMean visual acuity improved from baseline at the 6-month follow-up. Mean central retinal thickness decreased from baseline at the 6-month follow-up. CRVO group was associated with significantly lower visual acuity than BRVO group. However, visual acuity gain was similar in both groups. Independent of duration of symptoms, Duration of treatment effect following an injection appears to be limited for most patients. No ocular or systemic adverse reactions were noted.DiscussionIntravitreal injection of bevacizumab appears to be a new treatment option for patients with macular edema secondary to CRVO and BRVO.ConclusionIntravitreal injection of bevacizumab appears to be a new treatment option for patients with macular edema secondary to CRVO and BRVO.